

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)



(10) International Publication Number
WO 2022/119976 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/30 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/061486

(22) International Filing Date:

01 December 2021 (01.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/120,154	01 December 2020 (01.12.2020)	US
63/129,372	22 December 2020 (22.12.2020)	US
63/166,394	26 March 2021 (26.03.2021)	US

(71) Applicant: **APTEVO RESEARCH AND DEVELOPMENT LLC** [US/US]; 2401 4th Ave., Suite 1050, Seattle, Washington 98121 (US).

(72) Inventors; and

(71) Applicants: **PAVLIK, Peter** [US/US]; c/o APTEVO RESEARCH AND DEVELOPMENT LLC, 2401 4th Ave., Suite 1050, Seattle, Washington 98121 (US). **GROSS, Jane** [US/US]; c/o APTEVO RESEARCH AND DEVELOPMENT LLC, 2401 4th Ave., Suite 1050, Seattle, Washington 98121 (US).

(72) Inventors: **BIENVENUE, David Leonard**; c/o APTEVO RESEARCH AND DEVELOPMENT LLC, 2401 4th Ave., Suite 1050, Seattle, Washington 98121 (US). **HERNANDEZ-HOYOS, Gabriela**; c/o APTEVO RESEARCH AND DEVELOPMENT LLC, 2401 4th Ave., Suite 1050, Seattle, Washington 98121 (US). **MISHER, Lynda**; c/o APTEVO RESEARCH AND DEVELOPMENT LLC, 2401 4th Ave., Suite 1050, Seattle, Washington 98121 (US).

(74) Agent: **STEFFE, Eric K.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HETERODIMERIC PSMA AND CD3-BINDING BISPECIFIC ANTIBODIES

(57) Abstract: The present disclosure relates to antibodies that specifically bind to a tumor-associated antigen (TAA) such as PSMA and/or CD3, including bispecific antibodies that bind to a TAA (e.g., PSMA and CD3, and compositions comprising the same. These antibodies are useful for enhancing immune responses and for the treatment of disorders, including solid tumor cancers, for example, by increasing tumor localization.

WO 2022/119976 A1